食管癌病人检测血清β_2-微球蛋白的临床意义

Significance of detection of serum β_2-microglobulin in patients with esophageal cancer

目的 探讨 β2 微球蛋白 (β2 2microglobulin ,β2 MG)在食管癌的诊断、治疗及预后的临床价值。方法 用免疫放射分析法 (immunoradiometricassay,IRA)检测 71例食管癌病人、32例食管良性疾病病人的血清 β2 MG含量 ,以 4 0例健康人做对照。并对食管癌病人做了手术前后动态检测。结果 食管良性疾病组中血清 β2 MG含量为 1.6 9± 0 .5 1mg·L 1,对照组为 1.6 2± 0 .17mg·L 1,食管癌组为 2 .4 1± 0 .5 6mg·L 1。食管癌组高于对照组及食管良性疾病组 ,有显著性差异 (P <0 .0 5 ) ;术后 2周血清 β2 MG明显降低 ,与手术前相比 ,有显著性差异 (P <0 .0 5 ) ;在转移及复发时 ,其含量又升高。结论 食管癌病人血清 β2 MG水平升高并与肿瘤的消长有一定的相关性 ,对食管癌的治疗效果和预后判断有重要的临床价值。

Objective Clinical use of β 2 microglobulin (β 2 MG) in esophageal cancer in diagnosis?treatment and prognosis was evaluated. Methods The serum β 2 MG in 71 patients with esophageal cancer, in 32 patients with esophageal benign disease and in 40 normal persons as a control, was tested with immunoradiometric assay (IRA). Results The average concentration of disease β 2 MG was 1.69±0.51 mg·L -1 in esophageal benign disease group, 2.41±0.56 mg·L -1 in esophageal cancer group, and 1.62±0.17 mg·L -1 in the control. The statistic difference between cancer and benign or control group was P <0.05. The serum β 2 MG lowered down in esophageal cancer group after operation ( P <0.05),and remained higher at the time of metastasis or recurrence. Conclusion The serum β 2 MG level was higher in the patients with esophageal cancer, and was closely related to diagnosis? treatment and prognosis of esophageal cancer.